Drug Trial Radar · NCT02964403
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,700
Planned (sponsor's estimate)
Start
Dec 2016
Primary completion
Feb 2018
Study completion Aug 2018
Sponsor
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. The mechanism of indomethacin is dependent on COX-2 inhibitor. According to data, we design the project. The purpose of this study is to determine whether COX-2 inhibitor is effective on control of Post-ERCP pancreatitis.
Conditions
- Pancreatitis, Acute
Interventions
Cox-2Drug
IndomethacinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-ERCP PancreatitisTime frame: 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.